Non-Alcoholic Steatohepatitis (NASH) accounted for a 6.3% share of the global clinical trials within the Gastrointestinal therapy area in 2021, registering an increase of 2.6% when compared with the last ten-year average of 3.7% share, according to GlobalData.
Go deeper with GlobalData
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Industry sponsored trials outnumber non-industry sponsored trials for NASH
Industry sponsored trials held an 85.8% share of all the clinical trials for NASH indication in 2021, registering an increase of 31.3% when compared with the ten-year average of 54.5%. Non-industry sponsored trials accounted for a 14.2% share in 2021, marking a decrease of 31.3% over the ten-year average of 45.5%.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
Top regions of industry sponsored NASH trials
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAsia-Pacific was the top region for industry sponsored NASH trials, accounting for a 55.3% share in 2021, when compared with the five-year average of 34.5% and ten-year average of 29.7%.
North America was at the second position with a 47.4% share in 2021, over the five-year average of 64.4% and ten-year average of 56.1%, followed by Europe with a 19.7% share in 2021, as against five-year and ten-year averages of 35.1% and 42.7% respectively.
Middle East and Africa stood fourth with an 11.8% share in 2021, compared with the five-year average of 10.5% and ten-year average of 11.8%, followed by South and Central America with a 5.3% share in 2021, over five-year and ten-year averages of 7.1% and 4.3% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for industry sponsored NASH trials, accounting for a 47.4% share in 2021, as against the five-year average of 63.2% and ten-year average of 54.8%.
Australia held a 26.3% share in 2021, over the five-year average of 15.9% and ten-year average of 13.5%, followed by Japan with a 15.8% share in 2021, compared with the five-year and ten-year averages of 9.6% and 6.8% respectively.
Canada held a 13.2% share in 2021, as against the five-year average of 14.4% and ten-year average of 12.2%.
Poland held an 11.8% share in 2021, over the five-year and ten-year averages of 7.4% and 7.0% respectively.
Top regions of non-industry sponsored NASH trials
North America was the top region for non-industry sponsored NASH trials, accounting for a 35.7% share in 2021 when compared with the five-year average of 19.4% and ten-year average of 19.7%.
Asia-Pacific was at the second position with a 28.6% share in 2021, over the five-year and ten-year averages of 43.8% and 38.4% respectively, followed by Europe with a 28.6% share in 2021, as against the five-year average of 13.6% and ten-year average of 16.9%.
Middle East and Africa stood at the fourth position with a 7.1% share in 2021, compared with the five-year average of 23.2% and ten-year average of 25.0%, followed by South and Central America with a 0.0% share in 2021, over the five-year and ten-year averages of 0.0% and 0.5% respectively.
- Embed this chart
Embed this chart into your website Copy and paste the code below into your website to display the chart.
The US was the top country for non-industry sponsored NASH trials, accounting for a 35.7% share in 2021, as against the five-year average of 16.7% and ten-year average of 15.4%.
China held a 14.3% share in 2021, over the five-year average of 19.4% and ten-year average of 13.2%, followed by Denmark with a 14.3% share, compared with the five-year and ten-year averages of 2.5% and 1.9% respectively.
Japan held a 14.3% share in 2021, as against the five-year average of 7.1% and ten-year average of 11.0%.
Iran held a 7.1% share in 2021, over the five-year average of 19.0% and ten-year average of 20.4%.
Phase I trials lead industry sponsored clinical trials for NASH in 2021
Phase I trials held a 56.0% share of industry sponsored clinical trials for NASH in 2021, over the five-year average of 51.5% and ten-year average of 51.4%.
Phase II trials held a 37.4% share in 2021, as against the five-year average of 43.2% and ten-year average of 41.1%. Phase III trials held a 4.4% share in 2021, compared with the five-year and ten-year averages of 4.4% and 7.0% respectively.
Phase IV trials held a 2.2% share in 2021, over the five-year average of 0.9% and ten-year average of 0.4%.
Phase II trials lead non-industry sponsored clinical trials for NASH in 2021
Phase II trials held a 73.3% share of non-industry sponsored clinical trials for NASH in 2021, over the five-year average of 62.1% and ten-year average of 66.6%.
Phase III trials held a 20.0% share in 2021, as against the five-year average of 11.0% and ten-year average of 15.3%. Phase IV trials held a 6.7% share, compared with the five-year and ten-year averages of 13.2% and 9.9% respectively.
Phase I trials held a 0.0% share in 2021, over the five-year average of 13.8% and ten-year average of 8.2%.
Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.
